Symptoms, Gene Analysis, Diagnosis and Treatment of Neurofibromatosis type 1 (NF1) syndrome


Symptoms, Gene Analysis, Diagnosis and Treatment of Neurofibromatosis type 1 (NF1) syndrome


1Aqsa Javeed, 1Muzdalfa Zulfqar, 2Zeshan Haider

1Government College University Faisalabad
2University of Agriculture Faisalabad


Neurofibromatosis type 1 (NF1) is an autosomal predominant, mucocutaneous and inclination disorder. They include it in the development of benign and malignant tumors. Hereditary change in NF1 prompts changes in the outflow of cytoplasmic protein. 90% of all cases represent NF1 in neurofibromatosis. children tainted with NF1, they distinguish them inside a year.NF1 Patients ordinarily experience the ill effects of the café au laitt, freckling, and skeletal dysplasia. The GTPase actuating protein goes about as the principal job in NF1 quality, which fills in as a negative controlled by authoritative with the RAS protein. The neurofibromatosis type 1 quality is a 287-kilo premise of chromosome 17q11.2. In NF1 patients, the dermatologists distinguished the basic cutaneous highlights. Cutaneous neurofibroma has a variable pace of development during life expectancy. The threatening fringe nerve sheath tumor is plexiform neurofibromas. Palpebral plexiform neurofibroma is mono-sidelong. We have analyzed inherent dysplasia real criteria for NF1. The more exact technique to analyze NF1 in the patient is radiological indicative. An entire body MRI can test the interior nerve sheath tumor. They have announced that the research center analytic is extremely troublesome; However , it has done the RNA and ELISA tests somewhat. The treatment of NF1 patients is exceptionally troublesome because of the adequacy of the organ of the body. There is a biopsy, medical procedure, and radiotherapy performed for NF1 patients.


Keywords:  Symptoms, Gene Analysis, Diagnosis, Treatment, Neurofibromatosis type 1 (NF1) syndrome

Free Full-text PDF


How to cite this article:
Aqsa Javeed, Muzdalfa Zulfqar, Zeshan Haider. Symptoms, Gene Analysis, Diagnosis and Treatment of Neurofibromatosis type 1 (NF1) syndrome. American Journal of Biotechnology and Bioscience, 2019; 3:14


References:

1. Abdolrahimzadeh, Barmak, Domenica Carmen Piraino, Giorgio Albanese, Filippo Cruciani, and Siavash Rahimi. 2016. “Neurofibromatosis: An Update of Ophthalmic Characteristics and Applications of Optical Coherence Tomography.” Clinical Ophthalmology (Auckland, N.Z.) 10:851–60. https://doi.org/10.2147/OPTH.S102830.
2. Article, Original. 2002. “N 1.2 1.0,” no. fig 1.
3. Balcerzak, Waldemar, Andrzej T Dorobisz, and Piotr Czopnik. 2016. “Case Report Malignant Peripheral Sheath Tumour of the Neck Mimicking a Thyroid Tumour . A Case Report and a Literature Review from a Reference Centre for Endocrine Surgery Praca Z Ośrodka Referencyjnego W Chirurgii Endokrynologicznej,” 34–38.
4. Brown, J. A., S. M. Gianino, and D. H. Gutmann. 2010. “Defective cAMP Generation Underlies the Sensitivity of CNS Neurons to Neurofibromatosis-1 Heterozygosity.” Journal of Neuroscience 30 (16):5579–89. https://doi.org/10.1523/JNEUROSCI.3994-09.2010.
5. Cannon, Ashley, Mei-jan Chen, Peng Li, Kevin P Boyd, Amy Theos, David T Redden, and Bruce Korf. 2018. “Cutaneous Neurofibromas in Neurofibromatosis Type I : A Quantitative Natural History Study.” Orphanet Journal of Rare Diseases, 1–7.
6. Carroll, Steven L. 2016. “The Challenge of Cancer Genomics in Rare Nervous System Neoplasms Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.” The American Journal of Pathology 186 (3). American Society for Investigative Pathology:464–77. https://doi.org/10.1016/j.ajpath.2015.10.023.
7. Chang, Tiffany, Kimberly Krisman, Emily Harding Theobald, Jin Xu, Jon Akutagawa, Jennifer O Lauchle, Scott Kogan, Benjamin S Braun, and Kevin Shannon. 2013. “Brief Report Sustained MEK Inhibition Abrogates Myeloproliferative Disease in Nf1 Mutant Mice” 123 (1):335–39. https://doi.org/10.1172/JCI63193DS1.
8. Costi, R, P Caruana, L Sarli, V Violi, L Roncoroni, and C Bordi. 2001. “Ampullary Adenocarcinoma in Neurofibromatosis Type 1. Case Report and Literature Review.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 14 (11):1169–74. https://doi.org/10.1038/modpathol.3880454.
9. Cunha, K. S G, E. P. Barboza, E. P. Dias, and F. M. Oliveira. 2004. “Neurofibromatosis Type I with Periodontal Manifestation. A Case Report and Literature Review.” British Dental Journal 196 (8):457–60. https://doi.org/10.1038/sj.bdj.4811175.
10. Emmerich, Denise, Tomasz Zemojtel, Jochen Hecht, Peter Krawitz, Malte Spielmann, Jirko Kühnisch, Karolina Kobus, et al. 2015. “Somatic Neuro Fi Bromatosis Type 1 ( NF1 ) Inactivation Events in Cutaneous Neuro Fi Bromas of a Single NF1 Patient” 1 (October 2014):870–73. https://doi.org/10.1038/ejhg.2014.210.
11. Evans, D. Gareth R., Catherine O’Hara, Anna Wilding, Sarah L. Ingham, Elizabeth Howard, John Dawson, Anthony Moran, Vilka Scott-Kitching, Felicity Holt, and Susan M. Huson. 2011. “Mortality in Neurofibromatosis 1: In North West England: An Assessment of Actuarial Survival in a Region of the UK since 1989.” European Journal of Human Genetics 19 (11):1187–91. https://doi.org/10.1038/ejhg.2011.113.
12. Faden, Daniel L, Saurabh Asthana, Tarik Tihan, Joseph Derisi, and Michel Kliot. 2017. “Whole Exome Sequencing of Growing and Non-Growing Cutaneous Neurofibromas from a Single Patient with Neurofibromatosis Type 1,” 1–9. https://doi.org/10.1371/journal.pone.0170348.
13. Fayad, Laura M, Miriam A Bredella, Gordon J Harris, D Gareth Evans, Michael A Jacobs, Ralph Wenzel, Victor F Mautner, Eva Dombi, and Scott R Plotkin. 2016. “Current Whole-Body MRI Applications in the Neurofibromatoses,” 31–39.
14. Ferner, Rosalie E, and David H Gutmann. 2002. “International Consensus Statement on Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis 1 International Consensus Statement on Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis 1 1.” American Association for Cancer Research, no. 13:1573–77.
15. Ferner, Rosalie E, Susan M Huson, Nick Thomas, Celia Moss, Harry Willshaw, D Gareth Evans, Meena Upadhyaya, et al. 2007. “Guidelines for the Diagnosis and Management of Individuals with Neurofibromatosis 1,” 81–89. https://doi.org/10.1136/jmg.2006.045906.
16. Fisher, Michael J, Michael Loguidice, David H Gutmann, Robert Listernick, Rosalie E Ferner, Nicole J Ullrich, Roger J Packer, et al. 2012. “Visual Outcomes in Children with a Multicenter Retrospective Analysis” 14 (April 2018):790–97.
17. Halepota, Faiz M, Khalid Iqbal Talpur, Mahesh Kumar Luhano, Late Sher, and Muhammad Shaikh. 2014. “Years” 30 (1):33–37.
18. Hölzel, Michael, Sidong Huang, Jan Koster, Ingrid Øra, Arjan Lakeman, Huib Caron, Wouter Nijkamp, et al. 2010. “NF1 Is a Tumor Suppressor in Neuroblastoma That Determines Retinoic Acid Response and Disease Outcome.” Cell 142 (2):218–29. https://doi.org/10.1016/j.cell.2010.06.004.
19. Hwang, In Kyung, Seung Min Hahn, Hyo Sun Kim, Sang Kyum Kim, and Hyo Song Kim. 2017. “Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors : Different Clinical Features Associated with Neurofibromatosis Type 1” 49 (3):717–26.
20. “Institute of Medical Genetics, Cardiff University, Heath Park Campus, Cardiff, CF14 4XN, United Kingdom.” 2011, no. 3:937–51.
21. Jett, Kimberly, and Jan M. Friedman. 2010. “Clinical and Genetic Aspects of Neurofibromatosis 1.” Genetics in Medicine 12 (1):1–11. https://doi.org/10.1097/GIM.0b013e3181bf15e3.
22. Kar, Madhabananda, S V Suryanarayana Deo, Nootan Kumar Shukla, Ajay Malik, Sidharth Dattagupta, Bidhu Kumar Mohanti, and Sanjay Thulkar. 2006. “Malignant Peripheral Nerve Sheath Tumors ( MPNST ) – Clinicopathological Study and Treatment Outcome of Twenty-Four Cases” 8:1–8. https://doi.org/10.1186/1477-7819-4-55.
23. Karajannis, Matthias A, Rosalie E Ferner, Blood Disorders, and Great Maze Pond. 2016. “HHS Public Access” 27 (1):26–33. https://doi.org/10.1097/MOP.0000000000000169.NEUROFIBROMATOSIS-RELATED.
24. Karolak, Matthew R, Xiangli Yang, and Florent Elefteriou. 2015. “FGFR1 Signaling in Hypertrophic Chondrocytes Is Attenuated by the Ras-GAP Neuro Fi Bromin during Endochondral Bone Formation” 24 (9):2552–64. https://doi.org/10.1093/hmg/ddv019.
25. Karwacki, Marek W, and Wojciech Wozniak. 2011. “The Skeleton Abnormalities in Patients with Neurofibromatosis Type 1 : Important Consequences of Abnormal Gene Function.”
26. Kehrer-Sawatzki, Hildegard, Victor Felix Mautner, and David N. Cooper. 2017. “Emerging Genotype–phenotype Relationships in Patients with Large NF1 Deletions.” Human Genetics 136 (4). Springer Berlin Heidelberg:349–76. https://doi.org/10.1007/s00439-017-1766-y.
27. Kim, Aerang, and Douglas R Stewart. 2017. “Malignant Peripheral Nerve Sheath Tumors State of the Science : Leveraging Clinical and Biological Insights into Effective Therapies .” 2017.
28. Kim, Aerang, Douglas R Stewart, Karlyne M Reilly, David Viskochil, Markku M Miettinen, and Brigitte C Widemann. 2017. “Malignant Peripheral Nerve Sheath Tumors State of the Science : Leveraging Clinical and Biological Insights into Effective Therapies” 2017 (Table 1). Hindawi. https://doi.org/10.1155/2017/7429697.
29. Kolanczyk, Mateusz, Victor Mautner, Nadine Kossler, Rosa Nguyen, Jirko Kühnisch, Tomasz Zemojtel, Aleksander Jamsheer, et al. 2011. “MIA Is a Potential Biomarker for Tumour Load in Neurofibromatosis Type 1.” BMC Medicine 9 (1). BioMed Central Ltd:82. https://doi.org/10.1186/1741-7015-9-82.
30. Li, Kapsok, Chong Hyun Won, and Sang Eun Moon. 2005. “A Superficial Form of Malignant Peripheral Nerve Sheath Tumour Associated with Segmental Neurofibromatosis,” no. C:540–41. https://doi.org/10.1080/00015550510040022.
31. Malhotra, A, J Wright, and A Gajra. 2012. “Extra Gastrointestinal Stromal Tumor Treated with Imatinib in a Patient with Neurofibromatosis Type 1.” Journal of Gastrointestinal Oncology 3 (4):373–76. https://doi.org/10.3978/j.issn.2078-6891.2012.034.
32. Manuscript, Author. 2010. “NIH Public Access” 61 (1):1–16. https://doi.org/10.1016/j.jaad.2008.12.051.Neurofibromatosis.
33. Munhoz, E.A, C.L. Cardoso, E.S. Tolentino, B.S. Centurion, E.S. Goncales, E. Sant’ana, and Rubira-Bullen. 2010. “Von Recklinghausen â€TM S Disease – Diagnosis from Oral.” International Journal Odontostomat. 4 (2):179–83.
34. Nassr, Mohamed A, Carrie L Morris, Peter A Netland, and Zeynel A Karcioglu. 2009. “MAJOR REVIEW Intraocular Pressure Change in Orbital Disease.” Survey of Ophthalmology 54 (5). Elsevier Inc:519–44. https://doi.org/10.1016/j.survophthal.2009.02.023.
35. Nickle, Brandon, Blaze Emerson, Kimberly Hull, Brittany Smirnov, and Jaqueline Thomas. n.d. “Abdominal Pain : A Unique Presentation of Neurofibromatosis and Updated Review of the Condition,” 13–15.
36. Ornitz, David M, and Pierre J Marie. 2015. “Fibroblast Growth Factor Signaling in Skeletal Development and Disease,” 1463–86. https://doi.org/10.1101/gad.266551.115.).
37. Pasmant, Eric, and Dominique Vidaud. 2016. “EBioMedicine Neuro Fi Bromatosis Type 1 Molecular Diagnosis : The RNA Point of View.” EBIOM 7. The Authors:21–22. https://doi.org/10.1016/j.ebiom.2016.04.036.
38. Plotkin, Scott R, Anne C Albers, Dusica Babovic-vuksanovic, Jaishri O Blakeley, Xandra O Breakefield, Courtney M Dunn, D Gareth Evans, et al. 2015. “NIH Public Access” 164 (12):2969–78. https://doi.org/10.1002/ajmg.a.36754.Update.
39. Plotkin, Scott R, Miriam A Bredella, Wenli Cai, Ara Kassarjian, Gordon J Harris, Sonia Esparza, Vanessa L Merker, et al. 2012. “Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis” 7 (4). https://doi.org/10.1371/journal.pone.0035711.
40. Ratner, Nancy, and Shyra J Miller. 2016. “HHS Public Access” 15 (5):290–301. https://doi.org/10.1038/nrc3911.A.
41. Rhodes, Steven D, Wei Zhang, Dalong Yang, Hao Yang, and Shi Chen. 2015. “Dystrophic Spinal Deformities in a Neurofibromatosis Type 1 Murine Model” 1. https://doi.org/10.1371/journal.pone.0119093.
42. Scimeca, Ruth C. 2016. “High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma : A Case Report,” 774–81. https://doi.org/10.12659/AJCR.899754.
43. Sirvaitis, Skirmante, Ringaile Sirvaitis, Thomas Perusek, and Jorge Garcia-zuazaga. 2017. “Early Cutaneous Signs of Neurofibromatosis Type 1,” no. August:191–93. https://doi.org/10.1097/JDN.0000000000000316.
44. Stevenson, David A, Laurie J Moyer-mileur, D Ph, Mary Murray, Hillarie Slater, Xiaoming Sheng, D Ph, et al. 2008. “NIH Public Access” 150 (1):83–88.
45. Stewart, Douglas R, Jennifer L Sloan, Lawrence Yao, Andrew J Mannes, Chyi-chia Richard Lee, Raf Sciot, Luc De Smet, and Victor-felix Mautner. 2012. “The Digits in Neurofibromatosis Type 1” 47 (8):525–32. https://doi.org/10.1136/jmg.2009.073965.Diagnosis.
46. Sullivan, Kate, Jad El-hoss, Kate G R Quinlan, Nikita Deo, Fleur Garton, Jane T C Seto, Marie Gdalevitch, et al. 2014. “NF1 Is a Critical Regulator of Muscle Development and Metabolism” 23 (5):1250–59. https://doi.org/10.1093/hmg/ddt515.
47. Suzuki, Kayo, Taketoshi Yasuda, Takeshi Hori, and Kenta Watanabe. 2014. “An Intraosseous Malignant Peripheral Nerve Sheath Tumor of the Lumbar Spine without Neurofibromatosis : Case Report and Review of the Literature,” 1965–69. https://doi.org/10.3892/ol.2014.1987.
48. Valero, María Carmen, Yolanda Martín, Elisabete Hernández-Imaz, Alba Marina Hernández, Germán Meleán, Ana María Valero, Francisco Javier Rodríguez-Álvarez, Dolores Tellería, and Concepción Hernández-Chico. 2011. “A Highly Sensitive Genetic Protocol to Detect NF1 Mutations.” Journal of Molecular Diagnostics 13 (2). Elsevier Inc.:113–22. https://doi.org/10.1016/j.jmoldx.2010.09.002.
49. Williams, V. C., J. Lucas, M. A. Babcock, D. H. Gutmann, B. Korf, and B. L. Maria. 2009. “Neurofibromatosis Type 1 Revisited.” Pediatrics 123 (1):124–33. https://doi.org/10.1542/peds.2007-3204.
50. Wimmer, Katharina, Markus Eckart, Birgit Meyer-Puttlitz, Christa Fonatsch, and Torsten Pietsch. 2002. “Mutational and Expression Analysis of the NF1 Gene Argues against a Role as Tumor Suppressor in Sporadic Pilocytic Astrocytomas.” Journal of Neuropathology and Experimental Neurology 61 (10):896–902. https://doi.org/10.1093/jnen/61.10.896.